Insiders who reported open-market trades in the last 12 months at the companies Jeffrey S. Hackman files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jeffrey S. Hackman is a corporate insider, tracked as Chief Executive Officer, Director of FENNEC PHARMACEUTICALS INC. (FENC). InsiderAlpha holds 11 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Jeffrey S. Hackman submitted recently?
4 primary Form 4 filings in the last 90 days, covering 1 company.
Has Jeffrey S. Hackman been buying or selling stock?
Recorded transactions: 2 open-market purchases ($105K) and 0 open-market sales across all tracked filings.
Jeffrey S. Hackman is Chief Executive Officer, Director of FENNEC PHARMACEUTICALS INC. (FENC). 11 SEC Form 4 filings on record going back to 2025, most recently on 13 October 2026. Most recent open-market trade: bought $98K of FENC on 19 May 2025. Lifetime open-market purchases: $105K.
Recent transactions
13
The latest 13 SEC Form 4 transactions reported by Jeffrey S. Hackman.
InsiderAlpha's records for Jeffrey S. Hackman go back to 2025: 11 primary Form 4 filings, an average of 5.5 per year. The typical open-market purchase is $52K (2 buys totaling $105K). The largest single buy on record is $98K of FENC in 2025. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
